Altamira Therapeutics (NASDAQ:CYTO) Vs. ASRT, GLTO, ODT, EVFM, ZSAN, AGRX, OCUP, ABEO, ELDN, and JAGX
Should you be buying Altamira Therapeutics stock or one of its competitors? The main competitors of Altamira Therapeutics include Assertio (ASRT), Galecto (GLTO), Odonate Therapeutics (ODT), Evofem Biosciences (EVFM), Zosano Pharma (ZSAN), Agile Therapeutics (AGRX), Ocuphire Pharma (OCUP), Abeona Therapeutics (ABEO), Eledon Pharmaceuticals (ELDN), and Jaguar Health (JAGX). These companies are all part of the "pharmaceutical preparations" industry.
Altamira Therapeutics vs.
Galecto (NASDAQ:GLTO) and Altamira Therapeutics (NASDAQ:CYTO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation, risk and community ranking.
Galecto has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Altamira Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.
45.1% of Galecto shares are owned by institutional investors. Comparatively, 11.5% of Altamira Therapeutics shares are owned by institutional investors. 8.1% of Galecto shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Galecto had 3 more articles in the media than Altamira Therapeutics. MarketBeat recorded 6 mentions for Galecto and 3 mentions for Altamira Therapeutics. Galecto's average media sentiment score of 0.78 beat Altamira Therapeutics' score of -0.19 indicating that Galecto is being referred to more favorably in the media.
Altamira Therapeutics' return on equity of 0.00% beat Galecto's return on equity.
Galecto presently has a consensus price target of $11.50, suggesting a potential upside of 330.71%. Given Galecto's higher probable upside, analysts clearly believe Galecto is more favorable than Altamira Therapeutics.
Galecto received 21 more outperform votes than Altamira Therapeutics when rated by MarketBeat users.
Summary
Galecto beats Altamira Therapeutics on 7 of the 11 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CYTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Altamira Therapeutics (NASDAQ:CYTO) vs. Its Competitors
Altamira Therapeutics Competitors List
